Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
PH-15 by VistaGen Therapeutics for Cognitive Impairment: Likelihood of Approval
PH-15 is under clinical development by VistaGen Therapeutics and currently in Phase II for Cognitive Impairment. According to GlobalData, Phase...
Fasedienol by VistaGen Therapeutics for Anxiety Disorders: Likelihood of Approval
Fasedienol is under clinical development by VistaGen Therapeutics and currently in Phase III for Anxiety Disorders. According to GlobalData, Phase...
PH-284 by VistaGen Therapeutics for Cachexia: Likelihood of Approval
PH-284 is under clinical development by VistaGen Therapeutics and currently in Phase II for Cachexia. According to GlobalData, Phase II...
AV-101 by VistaGen Therapeutics for Neuropathic Pain (Neuralgia): Likelihood of Approval
AV-101 is under clinical development by VistaGen Therapeutics and currently in Phase I for Neuropathic Pain (Neuralgia). According to GlobalData,...
PH-80 by VistaGen Therapeutics for Vasomotor Symptoms of Menopause (Hot Flashes): Likelihood of Approval
PH-80 is under clinical development by VistaGen Therapeutics and currently in Phase II for Vasomotor Symptoms of Menopause (Hot Flashes)....
Risk adjusted net present value: What is the current valuation of VistaGen Therapeutics's AV-101?
AV-101 is a small molecule commercialized by VistaGen Therapeutics, with a leading Phase II program in Major Depressive Disorder. According...
Risk adjusted net present value: What is the current valuation of VistaGen Therapeutics's Itruvone?
Itruvone is a small molecule commercialized by VistaGen Therapeutics, with a leading Phase II program in Major Depressive Disorder. According...